​​The Senate Health, Education, Labor, and Pensions Committee held the second hearing in a series on the 340B drug savings program. Shifting away from the first hearing’s focus on hospitals, the Committee examined program oversight and questioned delays in implementing a final rule that would set drug ceiling prices. Many senators noted the benefits of 340B to their states, among others’ continued requests to clarify the program’s intent. Read the full testimonies here.​